---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Pharmacokinetics"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Pharmacokinetics. Topics: Absorption, dephosphorylation to psilocin, and distribution; Fixed oral doses of 15, 25, and 30 mg: maximal concentration, time to peak, and half-life; Weight-based escalating doses and equivalence of the 25 mg fixed dose; Metabolism: glucuronidation by UGT1A10 and UGT1A9; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Absorption, dephosphorylation to psilocin, and distribution

> “Psilocybin is rapidly dephosphorylated to psilocin, which is absorbed with Tmax values ranging from 1.8 to 4 h following oral administration.”
> “One study reported psilocin bioavailability at 52.7 ± 20%.”
> “The volume of distribution was extensive, ranging from 277 ± 92 L to 1016 L, suggesting significant tissue distribution.”
> “Elimination half-life varied across studies, ranging from 1.5 to 4 h.”

Source: [Meshkat et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12030428/)

<a id="topic-2.1.2.6.3-2"></a>

### Fixed oral doses of 15, 25, and 30 mg: maximal concentration, time to peak, and half-life

> “Mean (95% confidence interval) maximal psilocin concentrations were 11 ng/mL (10-13), 17 ng/mL (16-19), and 21 ng/mL (19-24) after the administration of 15, 25, and 30 mg psilocybin, respectively.”
> “Maximal concentrations were reached after an average of 2 hours.”
> “Elimination half-lives were 1.8 hours (1.7-2.0), 1.4 hours (1.2-1.7), and 1.8 hours (1.6-1.9) for 15, 25, and 30 mg psilocybin, respectively.”
> “Psilocin exhibited dose-proportional PKs.”
> “Body weight did not influence pharmacokinetics or the response to psilocybin.”
> “Neither plasma concentrations (Cmax or AUC values) nor subjective effects (Emax values) correlated significantly with body weight, BMI, GFR, or age.”

Source: [Holze et al. (2023)](https://doi.org/10.1002/cpt.2821)

<a id="topic-2.1.2.6.3-3"></a>

### Weight-based escalating doses and equivalence of the 25 mg fixed dose

> “No psilocybin was found in plasma or urine, and renal clearance of intact psilocin accounted for less than 2% of the total clearance.”
> “The pharmacokinetics of psilocin were linear within the twofold range of doses, and the elimination half-life of psilocin was 3 h (standard deviation 1.1).”
> “An extended elimination phase in some subjects suggests hydrolysis of the psilocin glucuronide metabolite.”
> “Simulation of fixed doses using the pharmacokinetic parameters suggest that an oral dose of 25 mg should approximate the drug exposure of a 0.3 mg/kg oral dose of psilocybin.”

Source: [Brown et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28353056/)

<a id="topic-2.1.2.6.3-4"></a>

### Metabolism: glucuronidation by UGT1A10 and UGT1A9

> “UGT1A10 exhibited the highest psilocin glucuronidation activity, whereas the activities of UGTs 1A9, 1A8, 1A7, and 1A6 were significantly lower.”
> “suggest that whereas psilocin may be subjected to extensive glucuronidation by UGT1A10 in the small intestine, UGT1A9 is likely the main contributor to its glucuronidation once it has been absorbed into the circulation.”

Source: [Manevski et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2835393/)

<a id="topic-2.1.2.6.3-5"></a>

### Metabolism: monoamine oxidase A, CYP2D6, and CYP3A4

> “MAO-A transformed psilocin into minimal amounts of 4-HIAA and 4-HTP.”
> “However, the CYP2D6 genotype did not influence psilocin plasma concentrations in the investigated study population.”
> “In conclusion, MAO-A, CYP2D6, and CYP3A4 are involved in psilocin’s metabolism.”
> “CYP2D6 and CYP3A4 seem to be involved to a minor extent in psilocin’s metabolism.”

Source: [Thomann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11089204/)

<a id="topic-2.1.2.6.3-6"></a>

### Elimination in urine as psilocin glucuronide, 4-HIAA, and unconjugated psilocin

> “Of the orally administered psilocybin (9.9 mg or 48.7 μmol psilocin in the 15 mg dose or 19.9 mg or 97.3 μmol in the 30 mg dose), an average of 20% was eliminated in urine as psilocin glucuronide and 33% was eliminated as 4-HIAA.”
> “Only 1.5% of the orally administered psilocybin was eliminated in urine as unconjugated psychoactive psilocin within 24 hours.”
> “Combined, ~ 54% of the administered dose of psilocybin is excreted renally within 24 hours as 4-HIAA, free psilocin, or psilocin glucuronide.”

Source: [Holze et al. (2023)](https://doi.org/10.1002/cpt.2821)

<a id="topic-2.1.2.6.3-7"></a>

### COMP360 single-dose pharmacokinetic and food-effect study in healthy volunteers

> “To investigate the PK of increasing doses of orally administered COMP360 (1 mg, 10 mg, 25 mg and 50 mg) in healthy volunteers in the single dose PK component.”
> “To investigate the PK of orally administered COMP360 (25 mg), following high-fat food intake relative to fasting conditions in the FE component.”

Source: [ISRCTN ISRCTN17905443](https://www.isrctn.com/ISRCTN17905443)

<a id="topic-2.1.2.6.3-8"></a>

### COMP360 pharmacokinetics in recurrent major depressive disorder

> “Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.”
> “Plasma concentrations of psilocybin, psilocin, 4-hydroxyindoleacetic acid (4-HIAA) and psilocin-O-glucuronide post-COMP360 administration on Day 1”

Source: [ClinicalTrials.gov NCT05733546](https://clinicaltrials.gov/study/NCT05733546)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
